Ovid Therapeutics
OVID
49 hedge funds and large institutions have $77.2M invested in Ovid Therapeutics in 2017 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 10 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
80% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 10
26% more capital invested
Capital invested by funds: $61.5M → $77.2M (+$15.7M)
17% more funds holding
Funds holding: 42 → 49 (+7)
2.44% more ownership
Funds ownership: 29.36% → 31.8% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$6.18M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$3.43M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.58M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$450K |
| 5 |
Morgan Stanley
New York
|
+$181K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.57M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$1.27M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.15M |
| 4 |
Jennison Associates
New York
|
-$821K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$775K |
OVID Hedge Fund Activity: Q4 2017 in Review
49 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q4 2017, worth a combined $77.2M — up 26% from $61.5M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new OVID positions and 5 closed out — a net gain of 7 holders — while 18 added to existing stakes and 10 trimmed.
The largest buyer was Putnam Investments, opening a new position worth an estimated $6.18M. The largest seller was Fidelity Investments, cutting an estimated $1.57M.
- 49 institutional investors held Ovid Therapeutics (OVID) as of Q4 2017, up from 42 in Q3 2017.
- Funds reported $77.2M of Ovid Therapeutics stock for Q4 2017, up 26% quarter-over-quarter.
- 12 funds opened new Ovid Therapeutics positions in Q4 2017 and 5 closed out, a net change of +7 holders.
- The largest Ovid Therapeutics buyer in Q4 2017 was Putnam Investments, an estimated $6.18M added.
- The largest Ovid Therapeutics seller in Q4 2017 was Fidelity Investments, an estimated $1.57M sold.
Based on aggregated 13F filings for Q4 2017.